Oxymatrine protects cardiac allografts by regulating immunotolerant cells

Organ transplantation is an effective treatment strategy for patients with irreversible organ failure or congenital organ dysfunction. Oxymatrine (OMT) is a quinolizidine alkaloid with protective and anti-inflammatory effects on tissues and organs. The objective of this study was to investigate whether OMT could exert protective effects in cardiac allografts by regulating immune cells. In vitro cell proliferation and co-culture experiments were used to measure the effects of OMT on splenocyte proliferation and differentiation. In the in vivo study, C57BL/6 mice transplanted with BALB/c cardiac grafts were randomly divided into untreated, low-dose OMT treated, middle-dose OMT treated, high-dose OMT treated, and rapamycin-treated groups. Haematoxylin and eosin and immu-nohistochemical staining were used to assess pathological changes in the grafts, and fluorescence-activated cell sorting analysis was performed to measure the percentages of immune cells. The results showed that, in the vitro study, OMT inhibited splenocyte proliferation, decreased the percentage of mature dendritic cells (DCs), and increased the percentage of regulatory T cells (Tregs) and regulatory B cells (Bregs). In the in vivo study, OMT exerted allograft protective effects by prolonging survival time, alleviating pathological damages to the cardiac allograft, decreasing intragraft CD3(+) cell and increasing intragraft Foxp3(+) cell infiltration, decreasing the per-centages of mature DCs, increasing the percentages of Tregs and Bregs, and inhibiting the function of DCs. conclusion, our study demonstrates that OMT exerted a protective effect on cardiac allografts by regulating immunotolerant cells. More in-depth studies of OMT may provide additional insight into the use of immuno-suppressive drugs as a post-transplantation treatment strategy.

Automated summary

The study demonstrated that oxymatrine (OMT) could protect cardiac allografts by regulating immunotolerant cells. In vitro, OMT inhibited splenocyte proliferation and changed the percentages of immune cells. In vivo, OMT prolonged survival time, alleviated pathological damages, and modulated immune cell infiltration in the cardiac allografts.